SCHEMBL4904913

SCHEMBL4904913

COc1cc(NC(=O)COc2ccc(C3CCCCC3)cc2)c(C(=O)O)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.56
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 1/20 0.53
GAA P10253 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
TP53 P04637 3/20 0.51
KDM4E B2RXH2 2/20 0.50
MAPT P10636 2/20 0.50
TSHR P16473 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HCAR2 Q8TDS4 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ALOX15 P16050 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419999 0.82 SERPINE1 (0.66) HIF1AMEN1KMT2APOLBGAA
SCHEMBL4913667 0.81 HCAR2 (0.65) HIF1AMEN1KMT2APOLBGAA
SCHEMBL3555469 0.80 HIF1A (0.56) HIF1AMEN1KMT2APOLBGAA
SCHEMBL3557167 0.78 HIF1A (0.54) HIF1AMEN1KMT2APOLBGAA
SCHEMBL6790520 0.76 LTB4R (0.49) MEN1KMT2AKDM4EMAPTTSHR
SCHEMBL3554708 0.76 GAA (0.55) HIF1AMEN1KMT2APOLBGAA
SCHEMBL4912688 0.75 DVL1 (0.69) MEN1KMT2APOLBGAANPC1
SCHEMBL3559758 0.74 GAA (0.53) HIF1AMEN1KMT2APOLBGAA
SCHEMBL29503108 0.73 KDM4E (0.58) MEN1KMT2AGAATP53KDM4E
SCHEMBL26651119 0.73 KDM4E (0.58) MEN1KMT2AGAATP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US claimed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US claimed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US claimed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO claimed
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US disclosed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US disclosed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US disclosed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus HCCS, ALAD, HAVCR2 HIF1A 399/4885MEN1 3867/4885KMT2A 1394/4885
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS HCCS, ALAD, HAVCR2 HIF1A 399/4885MEN1 3867/4885KMT2A 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.